A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS)
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Subjects who are newly diagnosed with symptomatic Multiple Myeloma (MM) and who:
Exclusion Criteria:
Heidelberg Melbourne, Victoria 3084, Australia
Fadingerstraße 1, 4020, Austria
Brussles, 1200, Belgium
Bucaresti, 030171, Romania
Lasi, 700483, Romania
Badalona-barcelona, 08916, Spain
La Laguna- Tenerife, 38320, Spain